EP Patent

EP3565553B1 — Intratumoral administration of sirolimus for treatment of prostate cancer

Assigned to Santen Pharmaceutical Co Ltd · Expires 2023-04-26 · 3y expired

What this patent protects

Patent listed against Rapamune.

Drugs covered by this patent

Patent Metadata

Patent number
EP3565553B1
Jurisdiction
EP
Classification
—
Expires
2023-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Santen Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.